The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.

Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

Vistagen plans to meet with the FDA to discuss a long-term registrational pathway, intending to combine positive data from ...

The chemotherapy-free regimen of Brukinsa and rituximab demonstrated significant progression free survival gains over standard chemoimmunotherapy.

The Baby-COMET study evaluated avalglucosidase alfa (40mg/kg IV every other week for 52 weeks) in 17 infants with infantile-onset Pompe disease.

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

The total costs of dementia are anticipated to be $818 billion in 2026, driven by quality-of-life losses for persons with dementia and care partners, according ...

The letter focuses exclusively on manufacturing control strategies for the biological component and contract manufacturing facility deficiencies. The Food and Drug Administration (FDA) has issued a ...

For ifosfamide, used to treat sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated.

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.

Lumvoa (veligrotug-vvze) is now FDA-approved to treat thyroid eye disease regardless of activity or duration, offering a new therapeutic option for both active and chronic phases. The Food and Drug ...

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.